Gene Editing Grows Up: CRISPR Is Now Cleared for Two-Year-Olds
On July 1, 2026, the FDA quietly did something that would have sounded like science fiction a decade ago: it approved a gene-editing therapy for two-year-olds.
The therapy is Casgevy, and the approval lowered its eligible age from 12 to 2 for both sickle cell disease with recurring pain crises and a severe blood disorder called beta thalassemia. It's the first — and so far only — gene therapy cleared for children this young with sickle cell disease, and the youngest anyone has been approved to receive a CRISPR-based medicine.
The stakes are immediate. Vertex Pharmaceuticals, which developed Casgevy with CRISPR Therapeutics, says about 5,500 additional U.S. children are now eligible. For families who have spent years watching a toddler cycle through hospitalizations for unpredictable, agonizing pain, that number isn't abstract.
But the same approval that widens the door sharpens a question the headlines mostly stepped around: what does it mean to offer a one-time, roughly $2 million cure to a child still in diapers?
It's worth remembering how new this is. Casgevy was approved for sickle cell disease in December 2023 — the first CRISPR-based therapy the FDA ever cleared. Beta thalassemia followed weeks later. That same day, a competing gene therapy, Bluebird bio's Lyfgenia, was approved at an even higher price of $3.1 million.
At the time, Dr. Alexis Thompson, who heads hematology at Children's Hospital of Philadelphia, called it "a pivotal moment in the field." Sickle cell disease had been neglected by drugmakers for generations despite affecting roughly 100,000 Americans, most of them Black, and two potentially curative options felt like a real turning point.
The approach is the same regardless of age: doctors collect a patient's own blood stem cells, use CRISPR to switch fetal hemoglobin production back on, and return the edited cells. That extra fetal hemoglobin keeps red blood cells from sickling — the process that drives the painful crises defining the disease. Vertex's data in children, first presented at hematology meetings, showed the edit works about as well in kids as in adults, with most treated beta thalassemia patients no longer needing transfusions.
Here's what gets lost when "CRISPR cures toddlers" becomes a headline: getting the edited cells back into a child is the easy part. Everything around it is grueling.
The full journey stretches close to a year. It starts with weeks of transfusions, then drugs and a blood-filtering process to pull stem cells out — which can take a week and sometimes has to be repeated. The cells go to a manufacturing facility for months. When they return, the child is admitted for four to six weeks and given busulfan, a chemotherapy that wipes out the existing bone marrow to make room for the edited cells.
That conditioning chemo is where the risk concentrates. In the children's trials, one child with beta thalassemia died — not from the gene editing, but from a liver complication caused by the busulfan. Vertex and independent doctors have been consistent that this is a known hazard of the conditioning regimen, the same one used in bone marrow transplants, not a failure of the CRISPR component. That distinction is medically real. It's also cold comfort to a parent weighing the odds.
And there's a consequence the coverage has underplayed: busulfan can damage fertility. In young children, it can destroy the cells that would one day produce eggs and sperm. Treatment centers offer fertility-preservation counseling first — but the standard tools, sperm banking and egg freezing, don't map onto a two-year-old. Lowering the age doesn't just widen access; it pushes an irreversible fertility decision onto parents of children far too young to weigh in.
Then there's the price. Casgevy's list price for the drug alone is $2.2 million. That doesn't include the ten to twelve months of hospital care, conditioning, and monitoring around the infusion. Counting all of it, insurers and state Medicaid programs pay closer to $3 million per patient.
Who pays matters enormously. Of the roughly 16,000 Americans with sickle cell disease severe enough to qualify, an estimated 60% are on Medicaid — turning a clinical breakthrough into a state-budget problem before it's anything else. In response, the Centers for Medicare & Medicaid Services created a payment model in which participating states get rebates from manufacturers if the therapy doesn't deliver. The Congressional Budget Office has noted that a genuine one-time cure could pay for itself over a lifetime by avoiding the recurring costs of managing the disease — though it cautions the long-term data doesn't yet exist.
The most sobering number isn't the price. It's how few people have actually been treated.
More than two years after Casgevy's original approval, uptake has stayed strikingly slow: Vertex reported just 64 patients received infusions across all of 2025, with 147 more starting the process through a first cell collection — nearly triple the year before. More than 500 patients have begun treatment since the therapy reached the market. Momentum is building. But the gap between "eligible" and "treated" remains vast.
The reasons aren't mainly about money anymore. They're logistical: few authorized treatment centers, the difficulty of collecting enough healthy stem cells from sickle cell patients, months of manufacturing, and the burden of committing a child to a year-long medical odyssey with a chemotherapy risk at its center.
Lowering the age to two adds 5,500 children to the eligible pool. It doesn't add a single treatment slot, shorten manufacturing, or make the busulfan any safer.
It would be easy to read the July approval as a simple story of progress. Some of it is: treating sickle cell disease before a child accumulates years of organ damage is a real argument, and the earlier the intervention, the more lifetime damage it may prevent.
But the more honest framing is that CRISPR has grown into the same hard problems facing every transformative-but-brutal medicine: access, cost, consent, and the distance between what's approved and what's achievable. A cure that reaches a few dozen people a year is a scientific triumph and a delivery failure at once.
For the parents of a two-year-old in the middle of a pain crisis, none of that will feel academic. They now have an option that didn't exist a month ago. Whether it becomes a real choice — rather than a theoretical one for a lucky few — is the question the next few years, not the last press release, will answer.
This piece is for general information, not medical advice; families considering gene therapy should talk through the specific risks and benefits with their child's care team.